Reuters
@Reuters·4.2M subscribers·86.9K videos
Novo Nordisk plunges after obesity drug trial disappoints | REUTERS
Posted
December 20, 2024
Views
2,894
Likes
34
Engagement
1.17%
December 20, 2024
2,894
34
1.17%
Every word spoken in this episode is indexed. Type any phrase to jump straight to the moment it was said.
Type any word or phrase that may have been spoken. Click a result to seek the player to that exact moment.
Try a name, a topic, or a quoted line
See what was published immediately before and after this episode.
1:31Now PlayingNovo Nordisk said its experimental next-generation obesity drug CagriSema helped patients cut their weight by 22.7% in a late-stage trial, below the 25% it had expected, wiping as much as $125 billion off its market value.
#News #novonordisk #wegovyweightloss #ozempic #Reuters #Newsfeed
Read the story here
👉 Subscribe
Keep up with the latest news from around the world
Follow Reuters on Facebook
Follow Reuters on Twitter
Follow Reuters on Instagram
Sentinel Indexing in Progress
Metadata and chapters are available. Claim extraction for this episode is pending.
All video content is delivered via YouTube embedded players in accordance with the YouTube Terms of Service. Sentinel provides research tools that promote discovery and accountability across political media.
